Job Stress Not Linked With Cancer Risk
Job stress was not directly associated with the risks of lung, breast, colorectal, or prostate cancer in a large retrospective study."Work-related psychosocial stress is unlikely to be an important risk... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 9, 2013 Category: Cancer & Oncology Source Type: news
Some HER2-Negative Cancers May Benefit from Anti-HER2 Therapy
SAN ANTONIO (IMNG) - Some breast cancers categorized as HER2 negative by conventional testing harbor mutations that may still render them amenable to therapy targeting this receptor, researchers reported... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 7, 2013 Category: Cancer & Oncology Source Type: news
Statins May Reduce Mortality in Hepatocellular Cancer
SAN FRANCISCO (IMNG) - The use of statins may reduce the risk of death in patients with hepatocellular cancer by 30%, a retrospective study of 639 patients suggests.Median overall survival from 2000 until... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 7, 2013 Category: Cancer & Oncology Source Type: news
Combination Therapy Better for Elderly With Colorectal Cancer
SAN FRANCISCO (IMNG) - Adding bevacizumab to capecitabine for first-line therapy for elderly patients with metastatic colorectal cancer significantly delayed disease progression and improved treatment... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 7, 2013 Category: Cancer & Oncology Source Type: news
Add-On Nab-Paclitaxel Extends Survival in Metastatic Pancreatic Cancer
SAN FRANCISCO (IMNG) - Median overall survival in 861 patients with metastatic pancreatic cancer increased from 6.7 months in those randomized to gemcitabine therapy to 8.5 months in patients receiving... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 7, 2013 Category: Cancer & Oncology Source Type: news
Second-Line Ramucirumab for Gastric/GEJ Adenocarcinoma Extends Survival
SAN FRANCISCO (IMNG) - A phase III clinical trial of an experimental monoclonal antibody for patients failing first-line treatment of metastatic gastric or gastroesophageal junction adenocarcinoma increased... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 5, 2013 Category: Cancer & Oncology Source Type: news
Adding Cetuximab Harmful in Esophageal Cancer Treatment
SAN FRANCISCO (IMNG) - A phase II/III clinical trial of adding cetuximab to chemoradiotherapy for localized esophageal cancer was stopped early when interim results showed greater toxicity, less completion... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 5, 2013 Category: Cancer & Oncology Source Type: news
New Tool Predicts Late Recurrence in Breast Cancer
SAN ANTONIO (IMNG) - A novel multigene signature known as the breast cancer index markedly outperformed the widely used Oncotype DX Recurrence Score and IHC4 tools in predicting late recurrences of estrogen... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 1, 2013 Category: Cancer & Oncology Source Type: news
Once-Daily Beta-Agonist for COPD Earns FDA Panel Support
SILVER SPRING, MD. (IMNG) - Olodaterol, an inhaled long-acting beta2-adrenergic agonist, is an effective bronchodilator and should be approved for the treatment of chronic obstructive pulmonary disease,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 1, 2013 Category: Cancer & Oncology Source Type: news
Poll: Public Doesn't See Cancer as a Death Sentence
People are optimistic about their chances of surviving cancer, according to a poll conducted in the United States and five other wealthy nations.Among respondents in all six countries, 48% said they did... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 1, 2013 Category: Cancer & Oncology Source Type: news
Prostatectomy vs Radiotherapy: 15-Year Functional Outcomes Are the Same
Fifteen years after treatment for localized prostate cancer, men who underwent radical prostatectomy reported no differences in urinary, bowel, or sexual function compared with men who underwent external-beam... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 1, 2013 Category: Cancer & Oncology Source Type: news
PET Projects Treatment Response in Adult Hodgkin's Disease
ATLANTA (IMNG) - Patients with a positron-emission tomography-confirmed response to chemotherapy for Hodgkin's lymphoma can be safely spared from radiotherapy without fear of compromising disease control,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 1, 2013 Category: Cancer & Oncology Source Type: news
Second-Line Agent for Gastroesophageal Adenocarcinoma Extends Survival
SAN FRANCISCO (IMNG) - A phase III clinical trial of an experimental monoclonal antibody for patients failing first-line treatment of metastatic gastric or gastroesophageal junction adenocarcinoma increased... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 31, 2013 Category: Cancer & Oncology Source Type: news
Lilly's Ramucirumab Makes an Impact in Tough-To-Treat Gastric Cancer, but Will It be Enough?
SAN FRANCISCO---Eli Lilly & Co.’s VEGF inhibitor ramucirumab made an impression when it showed single agent activity in second-line gastric cancer in the REGARD study and became one of the few non-chemotherapy... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 30, 2013 Category: Cancer & Oncology Source Type: news
Celgene's Abraxane Scores a Win Against Tough Pancreatic Cancer
Celgene Corp.'s nanoparticle formulation of paclitaxel, Abraxane, when added to standard of care gemcitabine, extended the life of advanced pancreatic cancer patients by 59% at one year and more than doubled... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 30, 2013 Category: Cancer & Oncology Source Type: news
